NASDAQ
11.28USD
+0.51 (+4.74%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
91.6M
P/E
—
EPS
—
Beta
0.35
52W range
9.71-17.5
Day range
10.93–11.67
Open
11.06
Prev close
10.77
Volume
396.8K
Avg volume
785.2K
Dividend
0.00
IPO
2026-07-21
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Freenome, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for FRNM: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
